Several clinical studies conducted in ovarian and other cancers demonstrated that response to paclitaxel treatment strongly correlated with no or low tau expression in treatment-naïve specimens, while high tau was indicative of the paclitaxel-resistant state (reviewed in Ref. This evidence concerns the gene MAPT and cancer.